Stay updated on Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.

Latest updates to the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 to the history; removed the funding notice and the earlier Revision: v3.4.1.SummaryDifference1.0%

- Check21 days agoChange DetectedAdded a Notice about a lapse in government funding stating that information may not be up to date and directing users to status sources. Updated the page revision to v3.4.1 and removed the previous v3.4.0 entry.SummaryDifference1.0%

- Check28 days agoChange DetectedThe page now shows a glossary toggle and introduces color-coded highlights (green for additions, red for deletions) in the history view, along with a revision note updated to v3.4.0 and minor wording changes such as capitalization of 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check42 days agoChange DetectedThe history now shows a new revision entry v3.3.4 and the removal of v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a new revision label 'Revision: v3.3.3' and removed the 'HHS Vulnerability Disclosure' footer link; these updates do not alter study information, eligibility criteria, or record history content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange DetectedFooter revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.